Drug intelligence / Profile preview

MVA-EbolaZ

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MVA-EbolaZ is an investigational vaccine designed to prevent Ebola virus disease. It is a recombinant modified vaccinia virus Ankara (MVA) vector that expresses the wild type (WT) glycoprotein (GP) from the Zaire strain of the Ebola virus. The vaccine aims to induce robust and durable humoral (antibody) and cellular (T-cell) immune responses against Ebola glycoprotein, thereby providing protection against the virus. It has been evaluated in clinical trials both as a standalone vaccine and as a booster in heterologous prime-boost regimens with cAd3-Ebola vaccines.

Other names: MVA-EBO Z

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on MVA-EbolaZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-EbolaZ.

Explore the full profile